Balyasny Asset Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21M Buy
+989,522
New +$19.8M 0.03% 672
2025
Q1
Sell
-140,075
Closed -$2.01M 3298
2024
Q4
$2.01M Buy
140,075
+95,820
+217% +$1.51M ﹤0.01% 1667
2024
Q3
$999K Sell
44,255
-36,056
-45% -$745K ﹤0.01% 1969
2024
Q2
$1.56M Buy
+80,311
New +$2.1M ﹤0.01% 1619
2024
Q1
Sell
-21,745
Closed -$1.22M 3133
2023
Q4
$1.22M Buy
+21,745
New +$946K ﹤0.01% 1609
2023
Q2
Sell
-676,861
Closed -$37.8M 2810
2023
Q1
$37.8M Buy
+676,861
New +$31.6M 0.09% 303
2022
Q3
Sell
-30,146
Closed -$1.36M 3270
2022
Q2
$1.36M Buy
+30,146
New +$1.56M ﹤0.01% 1625
2021
Q2
Sell
-19,751
Closed -$3.58M 2362
2021
Q1
$3.58M Sell
19,751
-39,312
-67% -$6.79M 0.02% 823
2020
Q4
$8.36M Buy
+59,063
New +$8.57M 0.05% 487
2020
Q3
Sell
-12,848
Closed -$1.15M 1613
2020
Q2
$1.15M Buy
+12,848
New +$1M 0.01% 805

Other funds holding TXG

Balyasny Asset Management's TXG Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in 10x Genomics (TXG) in Q1 2026: 989,522 shares worth $21M. The stake represents 0.03% of the portfolio and ranks #672 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in TXG as recently as Q4 2024.

Balyasny Asset Management first reported a position in TXG in Q2 2020 and has held it in 10 quarters since. The position peaked at $37.8M in Q1 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Balyasny Asset Management held 989,522 shares of 10x Genomics worth $21M as of Q1 2026.
  • 10x Genomics was a new Balyasny Asset Management position in Q1 2026.
  • 10x Genomics made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #672 holding.
  • Balyasny Asset Management first reported a position in 10x Genomics in Q2 2020 and has held it in 10 quarters since.
  • Balyasny Asset Management's 10x Genomics position peaked at $37.8M in Q1 2023.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.